RJA
CDTX

Raymond James & Associates’s Cidara Therapeutics CDTX Stock Holding History

Raymond James & Associates’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-584
Closed -$7K – 3937
2022
Q3 		$7K Buy
+584
New +$8.06K ﹤0.01% 3874
2020
Q3 		– Sell
-692
Closed -$51K – 3596
2020
Q2 		$51K Buy
+692
New +$44.8K ﹤0.01% 3373
2020
Q1 		– Sell
-588
Closed -$45K – 3531
2019
Q4 		$45K Sell
588
-62
-10% -$2.84K ﹤0.01% 3562
2019
Q3 		$26K Sell
650
-12,100
-95% -$407K ﹤0.01% 3527
2019
Q2 		$428K Sell
12,750
-2,233
-15% -$92.8K ﹤0.01% 2784
2019
Q1 		$794K Sell
14,983
-1,585
-10% -$86.9K ﹤0.01% 2338
2018
Q4 		$779K Buy
16,568
+4,578
+38% +$327K ﹤0.01% 2232
2018
Q3 		$1.05M Buy
11,990
+2,196
+22% +$194K ﹤0.01% 2227
2018
Q2 		$1.02M Buy
9,794
+4,996
+104% +$472K ﹤0.01% 2199
2018
Q1 		$384K Buy
4,798
+3,549
+284% +$485K ﹤0.01% 2729
2017
Q4 		$170K Sell
1,249
-311
-20% -$47.2K ﹤0.01% 3112
2017
Q3 		$253K Buy
1,560
+314
+25% +$44.7K ﹤0.01% 2894
2017
Q2 		$187K Buy
+1,246
New +$172K ﹤0.01% 3001

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's CDTX Position: Q4 2022 in Review

Raymond James & Associates sold out of Cidara Therapeutics (CDTX) in Q4 2022, closing a stake of 584 shares — an estimated $7K sold.

Raymond James & Associates first reported a position in CDTX in Q2 2017 and held it in 13 quarters. The position peaked at $1.05M in Q3 2018. 42 funds tracked by Wall St. Rank hold CDTX as of Q4 2022.

  • Raymond James & Associates reported no remaining Cidara Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 584 Cidara Therapeutics shares in Q4 2022, an estimated $7K.
  • Raymond James & Associates first reported a position in Cidara Therapeutics in Q2 2017 and held it in 13 quarters.
  • Raymond James & Associates's Cidara Therapeutics position peaked at $1.05M in Q3 2018.
  • 42 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.